Harbin Medisan Pharmaceutical Co Ltd (002900) - Total Liabilities
Based on the latest financial reports, Harbin Medisan Pharmaceutical Co Ltd (002900) has total liabilities worth CN¥1.70 Billion CNY (≈ $249.39 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Harbin Medisan Pharmaceutical Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Harbin Medisan Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Harbin Medisan Pharmaceutical Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Harbin Medisan Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Harbin Medisan Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Schoeller-Bleckmann Oilfield Equipment Aktiengesellschaft
VI:SBO
|
Austria | €460.39 Million |
|
PKU HealthCare Corp Ltd
SHE:000788
|
China | CN¥397.66 Million |
|
Hunan Lead Power Dazhi Technology Inc Co
SHE:300530
|
China | CN¥1.20 Billion |
|
Jinfa Labi Maternity & Baby Articles Co Ltd
SHE:002762
|
China | CN¥146.19 Million |
|
TWC Enterprises Ltd
TO:TWC
|
Canada | CA$146.23 Million |
|
I-Mab
NASDAQ:IMAB
|
USA | $18.50 Million |
|
Net Holding AS
IS:NTHOL
|
Turkey | TL39.93 Billion |
|
Utechzone Co Ltd
TWO:3455
|
Taiwan | NT$1.41 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Harbin Medisan Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 002900 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Harbin Medisan Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Harbin Medisan Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual total liabilities of Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.64 Billion ≈ $239.44 Million |
+26.38% |
| 2023-12-31 | CN¥1.29 Billion ≈ $189.46 Million |
+5.71% |
| 2022-12-31 | CN¥1.22 Billion ≈ $179.23 Million |
+29.06% |
| 2021-12-31 | CN¥949.04 Million ≈ $138.88 Million |
+37.31% |
| 2020-12-31 | CN¥691.18 Million ≈ $101.14 Million |
-15.75% |
| 2019-12-31 | CN¥820.44 Million ≈ $120.06 Million |
+50.88% |
| 2018-12-31 | CN¥543.78 Million ≈ $79.57 Million |
+55.90% |
| 2017-12-31 | CN¥348.80 Million ≈ $51.04 Million |
-2.57% |
| 2016-12-31 | CN¥358.01 Million ≈ $52.39 Million |
+10.17% |
| 2015-12-31 | CN¥324.95 Million ≈ $47.55 Million |
-10.06% |
| 2014-12-31 | CN¥361.30 Million ≈ $52.87 Million |
-26.66% |
| 2013-12-31 | CN¥492.63 Million ≈ $72.09 Million |
+30.92% |
| 2012-12-31 | CN¥376.29 Million ≈ $55.06 Million |
-- |
About Harbin Medisan Pharmaceutical Co Ltd
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium foli… Read more